CAM Use May Affect Breast Cancer Patients' Chemo Decisions

This article originally appeared here.
Share this content:
CAM Use May Affect Breast Cancer Patients' Chemo Decisions
CAM Use May Affect Breast Cancer Patients' Chemo Decisions

FRIDAY, May 13, 2016 (HealthDay News) -- Women with early-stage breast cancer who utilize complementary and alternative medicine (CAM) may delay recommended chemotherapy, according to research published online May 12 in JAMA Oncology.

Heather Greenlee, Ph.D., assistant professor of epidemiology at the Columbia University Mailman School of Public Health in New York City, and colleagues studied 685 women with early-stage breast cancer, all under the age of 70. Of all the women in the study, 87 percent said they used some type of CAM, most commonly dietary supplements and mind-body practices. Many women used two CAM therapies, and 38 percent used three or more.

In all, 306 women were advised to undergo chemotherapy. After a year, 89 percent of these women had started treatment. Among the other women, for whom chemotherapy was optional, only 36 percent opted for treatment. Use of dietary supplements and high CAM index scores were related to the decision whether or not to have chemotherapy, while the use of mind-body practices was not related to starting chemotherapy. No association between starting chemotherapy and alternative therapy was found among women for whom chemotherapy was optional.

"A cautious interpretation of results may suggest to oncologists that it is beneficial to ascertain CAM use among their patients, especially dietary supplement use, and to consider CAM use as a potential marker of patients at risk of not initiating clinically indicated chemotherapy," the authors conclude.

Abstract
Full Text
Editorial

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Approves Zejula for Certain Female Cancers

FDA Approves Zejula for Certain Female Cancers

PARP inhibitor may help fight tumors affecting the ovaries, fallopian tubes, or peritoneum

USPSTF: Evidence Lacking for Celiac Dz Screen in Asymptomatic

USPSTF: Evidence Lacking for Celiac Dz Screen in ...

Insufficient evidence for weighing benefits, harms of screening for celiac disease in asymptomatic

Lap, Abdominal Hysterectomy Equal for Early Endometrial CA

Lap, Abdominal Hysterectomy Equal for Early Endometrial CA

Equivalent disease-free survival at 4.5 years for stage I endometrial cancer with TAH, TLH

is free, fast, and customized just for you!

Already a member?

Sign In Now »